Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has reported impressive financial results for the second quarter of fiscal year 2026, demonstrating strong growth across key metrics.

Financial Highlights

The company's performance for Q2 FY26 shows significant year-over-year improvements:

Revenue Growth

Acutaas Chemicals reported a robust 25.70% year-over-year increase in revenue, reaching ₹3,061.90 crore in Q2 FY26, up from ₹2,435.90 crore in the same quarter last year. This substantial growth reflects the company's strong market position and effective business strategies.

Profitability Surge

The company's profitability saw a remarkable improvement, with net profit nearly doubling to ₹730.00 crore, compared to ₹377.00 crore in Q2 FY25. This 93.60% increase in net profit underscores Acutaas Chemicals' enhanced operational efficiency and successful business expansion efforts.

EBITDA Performance

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed an impressive growth of 100.80%, rising to ₹966.00 crore from ₹481.00 crore in the corresponding quarter of the previous year. The EBITDA margin expanded significantly to 31.55% from 19.75%, representing an improvement of 1,180 basis points year-over-year.

Conclusion

Acutaas Chemicals' Q2 FY26 results demonstrate the company's ability to drive growth and improve profitability in a competitive market. The significant increases in revenue, EBITDA, and net profit reflect the company's strong fundamentals and effective execution of its business strategies.

Investors and market observers may view these results as indicative of Acutaas Chemicals' potential for sustained growth and value creation in the specialty chemicals sector. However, it's important to note that future performance may be subject to various market factors and industry dynamics.

Acutaas Chemicals Limited, a leading player in the specialty chemicals sector, held its 18th Annual General Meeting (AGM) on September 25, 2025, where shareholders approved several significant resolutions, including the reappointment of key leadership positions and the adoption of financial statements.

Leadership Continuity

The shareholders approved the reappointment of Nareshkumar Ramjibhai Patel as Managing Director and Executive Chairman for a five-year term from May 1, 2026, to April 30, 2031. This decision ensures continuity in the company's top leadership, with Patel bringing over two decades of experience in the chemical and pharma industry.

Additionally, Chetankumar Chhaganlal Vaghasia and Virendra Nath Mishra were reappointed as Whole Time Directors for five-year terms. Vaghasia's term will run from May 1, 2026, to April 30, 2031, while Mishra's term is set from April 1, 2026, to March 31, 2031.

Independent Director Reappointments

The meeting also saw the reappointment of two independent directors. Richa Manoj Goyal and Hetal Madhukant Gandhi were both approved for second terms of five consecutive years. Goyal, a practicing company secretary with over 20 years of experience in corporate laws and intellectual property rights, will serve from April 1, 2026, to March 31, 2031. Gandhi, a chartered accountant with three decades of experience in financial services, will serve from April 28, 2026, to April 27, 2031.

Financial Approvals and Dividend Declaration

Shareholders adopted the audited financial statements for the fiscal year ended March 31, 2025, along with the reports of the Board of Directors and Auditors. A final dividend of 30% (₹1.50 per equity share) for the financial year 2024-25 was declared, reflecting the company's strong financial performance.

Other Key Resolutions

The AGM also approved the ratification of remuneration for cost auditors for the financial year 2025-26 and the appointment of M/s KSPS & Co. LLP as the Secretarial Auditors of the company for a five-year term from FY 2025-26 to FY 2029-30.

Shareholder Participation and Voting

The meeting, conducted through video conferencing, saw active participation from shareholders. All resolutions were passed with significant majority, demonstrating strong shareholder support for the company's governance and strategic direction.

Acutaas Chemicals Limited's focus on maintaining leadership stability while ensuring robust corporate governance through the reappointment of experienced independent directors signals the company's commitment to sustained growth and shareholder value creation in the specialty chemicals sector.